Limbal function and tear protein changes in glaucoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational study enrolling about 90 participants divided into healthy controls, newly diagnosed glaucoma/ocular hypertension (medication <3 months), long-term treated patients (medication >1 year), and unilateral cases. Investigators will measure corneal epithelial and limbal epithelial thickness as a surrogate for limbal stem cell function and collect tear fluid for proteomic analysis. The goal is to link structural changes at the limbus with specific changes in the tear proteome associated with disease and medication exposure. Standard exclusion criteria remove eyes with prior corneal/conjunctival surgery, severe ocular surface disease, or other conditions that would confound measurements.

Why it matters

Who can join: the full rules

Inclusion Criteria:

i. Age ≥ 18 years. ii. Healthy Control Group: No diagnosis of glaucoma or ocular hypertension. iii. Glaucoma, Newly Diagnosed Group: Diagnosed with angle-closure glaucoma, open-angle glaucoma, or ocular hypertension; antiglaucoma medication usage for less than 3 months.

iv. Glaucoma, Long-term Medication Group: Diagnosed with angle-closure glaucoma, open-angle glaucoma, or ocular hypertension; continuous use of intraocular pressure-lowering medications for more than 1 year.

v. Glaucoma, Unilateral Group: Diagnosed with unilateral glaucoma or ocular hypertension; only one eye receiving intraocular pressure-lowering treatment.

Exclusion Criteria:

i. History of severe ocular trauma, chemical burns, corneal ulcers, Stevens-Johnson syndrome with ocular involvement, or ocular graft-versus-host disease.

ii. History of corneal surgery, conjunctival surgery, trabeculectomy, or glaucoma drainage device implantation.

iii. Presence of ocular surface irregularity or limbal dysfunction due to conditions other than glaucoma or dry eye disease.

Where it's running

• National Taiwan University Hospital Hsinchu Branch
  Hsinchu, Taiwan Recruiting

Study contacts

• Study coordinator: Wei-Lun Huang, MD
• Email: weilunhuang@ntu.edu.tw
• Phone: 886-3-6677600

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Imaging the effect of Netarsudil on the eye’s drainage system in glaucoma and ocular hypertension

  This study tests whether netarsudil eye drops change the trabecular meshwork’s structure compared with placebo in adults with ocular hypertension or open-angle glaucoma.

  Recruiting Phase 4 Indiana University · Bloomington, Indiana · NCT07588152

• Bimatoprost implant with SpyGlass intraocular lens vs timolol drops for cataract patients with glaucoma

  This study tests whether placing a bimatoprost implant together with a SpyGlass intraocular lens during cataract surgery controls eye pressure better than daily timolol drops in people with mild to moderate open‑angle glaucoma or ocular hypertension.

  Recruiting Phase 3 SpyGlass Pharma, Inc. · San Antonio, Texas · NCT07218796

• Combining a bimatoprost eye implant with the SpyGlass intraocular lens versus timolol eye drops for people having cataract removal

  This study will test whether placing a small bimatoprost implant with the SpyGlass intraocular lens at the time of cataract surgery better controls eye pressure than using timolol eye drops in people with mild to moderate open-angle glaucoma or ocular hypertension.

  Recruiting Phase 3 SpyGlass Pharma, Inc. · Houston, Texas · NCT07218783

• Eye-surface inflammation after replacing nightly preserved glaucoma drops with a Durysta implant

  We will try a single Durysta intracameral implant to see if cutting back nightly preserved glaucoma drops reduces eye-surface inflammation in people with open-angle glaucoma or ocular hypertension who are pseudophakic and have signs of surface damage.

  Recruiting Phase 4 University of Miami · Miami, Florida · NCT07217678

• Sustained-release TimoD (timolol) implant placed during cataract surgery for glaucoma or ocular hypertension

  This trial tests whether a small TimoD timolol implant placed during cataract surgery is safe and well tolerated in people with glaucoma or ocular hypertension.

  Recruiting Phase 1/2 EyeD Pharma · Panama City · NCT07036510

• Evaluating the long-term safety and effectiveness of a modified silicone tube for glaucoma treatment

  This study is testing a new silicone tube to see if it safely helps people with glaucoma manage their eye pressure and maintain good vision over the long term.

  Recruiting Davinci LTD · Tbilisi · NCT06691555

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.